AVP-786-28

DRUG2 trials

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.

Conditions

Agitation in Participants With Dementia of the Alzheimer's TypeNeurobehavioral Disinhibition

Phase 2

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury

CompletedNCT03095066

Otsuka Pharmaceutical Development & Commercialization, Inc.Neurobehavioral Disinhibition

Start: 2017-05-30End: 2022-08-31Updated: 2025-10-29

Phase 3

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type

CompletedNCT02442778

Otsuka Pharmaceutical Development & Commercialization, Inc.Agitation in Participants With Dementia of the Alzheimer's Type

Start: 2015-11-11End: 2019-09-09Updated: 2022-09-09

Related Papers

Deuterated dextromethorphan/quinidine for agitation in Alzheimer’s disease

Neural Regeneration Research2021-09-1915 citations